Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Entero Therapeutics Inc ENTO

Healthcare Biotechnology
Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of... see more

Recent & Breaking News (NDAQ:ENTO)

First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

GlobeNewswire March 13, 2023

HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors

GlobeNewswire March 13, 2023

First Wave BioPharma Announces Second Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation in Cystic Fibrosis

GlobeNewswire March 10, 2023

First Wave BioPharma Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation

GlobeNewswire March 9, 2023

First Wave BioPharma to Participate in 'Fireside Chat' at the 35th Annual Roth Conference

GlobeNewswire February 28, 2023

First Wave BioPharma Announces Phase 2 Adrulipase Combination Trial Data to be Presented at the 2023 Digestive Disease Week (DDW) Conference

GlobeNewswire February 21, 2023

First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

GlobeNewswire February 13, 2023

First Wave BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement

GlobeNewswire February 7, 2023

First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis

GlobeNewswire February 2, 2023

First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

GlobeNewswire January 31, 2023

First Wave BioPharma to Present at the BIO CEO & Investor Conference

GlobeNewswire January 30, 2023

First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio

GlobeNewswire January 25, 2023

First Wave BioPharma to Present at Sequire Biotechnology Conference

GlobeNewswire January 24, 2023

First Wave BioPharma Provides Update on IND Filing For Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency

GlobeNewswire January 13, 2023

First Wave BioPharma Announces Results of Special Meeting of Stockholders

GlobeNewswire January 13, 2023

First Wave BioPharma Announces Adjournment of Special Meeting

GlobeNewswire January 9, 2023

ZyVersa Therapeutics Appoints Three New Board Members

PR Newswire January 5, 2023

First Wave BioPharma to Participate in BIO Partnering @ JPM During "J.P. Morgan Week 2023"

GlobeNewswire December 12, 2022

First Wave BioPharma Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase

GlobeNewswire December 5, 2022

First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase

GlobeNewswire November 30, 2022